ORGO
Organogenesis Holdings Inc
NASDAQ: ORGO · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$2.59
+0.00% today
Updated 2026-05-27
Market cap
$319.11M
P/E ratio
—
P/S ratio
0.62x
EPS (TTM)
$-0.12
Dividend yield
—
52W range
$2 – $7
Volume
1.7M
WallStSmart proprietary scores
44
out of 100
Grade: D
Sell
Investment rating
6.0
Growth
B8.5
Quality
A3.5
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
3.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$3.00
+15.83%
12-Month target
$2.86
+10.42%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.35 — safe zone
+ Free cash flow $17.98M — positive
+ Debt/equity 0.19x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.53%
- Revenue declining -57.10% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $450.89M | $433.14M | $482.04M | $563.03M | $514.70M |
| Net income | $15.53M | $4.95M | $861000.00 | $37.03M | $-56.16M |
| EPS | — | — | — | — | $-0.12 |
| Free cash flow | $-9.04M | $6.55M | $4.18M | $-24.46M | $17.98M |
| Profit margin | 3.44% | 1.14% | 0.18% | 6.58% | 0.53% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-09 | LEIBOWITZ, ARTHUR S | Buy | 5,000 | $2.68 |
| 2026-03-09 | DRISCOLL, MICHAEL JOSEPH | Buy | 10,000 | $2.67 |
| 2026-03-01 | CAVORSI, ROBERT | Sale | 700 | $3.21 |
Peer comparison
Smart narrative
Organogenesis Holdings Inc trades at $2.59. Our Smart Value Score of 44/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.35, it sits in the safe zone. TTM revenue stands at $514.70M. with profit margins at 0.53%.
Frequently asked questions
What is Organogenesis Holdings Inc's stock price?
Organogenesis Holdings Inc (ORGO) trades at $2.59, on a P/S of 0.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Organogenesis Holdings Inc overvalued?
Organogenesis Holdings Inc carries a Smart Value Score of 44/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Organogenesis Holdings Inc (ORGO)?
The 12-month analyst consensus target is $3.00, about 15.8% above the current $2.59. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Organogenesis Holdings Inc's revenue?
Organogenesis Holdings Inc's trailing twelve-month revenue is $514.70M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Organogenesis Holdings Inc's Altman Z-Score is 3.35, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.62x
ROE0.73%
Beta1.33
50D MA$2.44
200D MA$3.85
Shares out0.13B
Float0.06B
Short ratio—
Avg volume1.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—